Abstract
We evaluated the diagnostic usefulness of measurement of the soluble cytokeratin 19 fragment, a new tumor marker, in 391 patients with lung cancer and in 424 patients with benign lung diseases. Serum concentrations of cytokeratin 19 fragment were measured by a sandwich ELISA (CYFRA). The cut‐off value was defined as 3.5 ng/ml, which is associated with a specificity of 85% for benign lung diseases. CYFRA had a high sensitivity (57.5%) in all subjects with lung carcinoma, and had a higher sensitivity for squamous cell carcinoma (73.1%, n = 141) than squamous cell carcinoma‐related antigen (61.0%). CYFRA was associated with a relatively high sensitivity (42.1%) in early‐stage squamous cell carcinoma (stage I, based on the classification of the Japan Lung Cancer Society), but the CYFRA titer was higher in advanced squamous cell carcinoma than in early‐stage squamous cell carcinoma. Our findings suggest that CYFRA is potentially useful for diagnosis and monitoring of lung carcinoma, especially for squamous cell carcinoma.
Keywords: Tumor marker, Cytokeratin fragment, Lung cancer
Full Text
The Full Text of this article is available as a PDF (330.4 KB).
REFERENCES
- 1. ) Fuchs , E.Keratins as biochemical markers of epithelial differentiation . Trends Genet. , 4 , 277 – 281 ( 1988. ). [DOI] [PubMed] [Google Scholar]
- 2. ) Broers , J. L. V. , Ramaekers , F. C. S. , Rot , M. K. , Oostendrop , T. , Huysmans , A. , Muijen , G. N. P. , Wagenaar , S. and Vooijs , O. P. , Cytokeratins in different types of human lung cancer as monitored by chain‐specific monoclonal antibodies . Cancer Res. , 48 , 3221 – 3229 ( 1988. ). [PubMed] [Google Scholar]
- 3. ) Akoun , G. M. , Scarna , H. M. and Milleron , B.Serum neuron‐specific enolase . Chest , 87 , 39 – 43 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Carney , D. N. , Marangos , P. J. and Ihde , D. C.Serum neuron‐specific enolase: a marker for disease extent and response to therapy of small‐cell lung cancer . Lancet , iii , 583 – 585 ( 1982. ). [DOI] [PubMed] [Google Scholar]
- 5. ) Body , J. J. , Sculier , J. P.Raymakers , N. , Paesmans , M. , Ravez , P. , Libert , P. , Richez , M. , Dabouis , G. , Lacroix , H. , Bureau , G. , Thiriaux , J. , Lecomte , J. , Brohee , D. , Momrnen , P. , Frühling , J. and Klastersky , J.Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer . Cancer , 65 , 1552 – 1556 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Shinkai , T. , Saijo , N. , Tominaga , K. , Eguchi , K. , Shimizu , E. , Sasaki , Y. , Fujita , J. , Futami , H. , Ohkura , H. and Suemasu , K.Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy . Cancer , 57 , 1318 – 1323 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 7. ) Moll , R.Differenzierung und Entdifferenzierung im Spiegel der Intermediarfilament‐Expression: Untersuchungen an Normalen, Alterierten und Malignen Epithelien mit Betonung der Cytokeratine , Verh. Dtsch. Ges. Pathol. , 75 , 446 – 459 ( 1991. ). [PubMed] [Google Scholar]
- 8. ) Pujol , J. L. , Grenier , J. , Daures , J. P. , Daver , A. , Pujol , H. and Michel , F. B.Serum fragment of cytokratin subunit 19 measured by CYFRA 21‐1 immunoradiometric assay as a marker of lung cancer . Cancer Res. , 53 , 61 – 66 ( 1993. ). [PubMed] [Google Scholar]
- 9. ) Ebert , W. , Leichtweis , B. , Schapohler , B. and Muley , T.The new tumor marker CYFRA is superior to SCC antigen and CEA in the primary diagnosis of lung cancer . Tumordiagn. Ther. 14 , 91 – 99 ( 1993. ). [Google Scholar]
- 10. ) Stieber , P. , Hasholzner , IL. , Bodenmüller , H. , Nagel , D. , Sunder‐Plassmann , L. , Dienemann , H. , Meier , W. and Fateh‐Moghadam , A.CYFRA21‐1 a new marker in lung cancer . Cancer , 72 , 707 – 713 ( 1993. ). [DOI] [PubMed] [Google Scholar]